<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1476-5381</journal-id><journal-id journal-id-type="publisher-id">BPH</journal-id><journal-title-group><journal-title>British Journal of Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0007-1188</issn><issn pub-type="epub">1476-5381</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7323156</article-id><article-id pub-id-type="doi">10.1111/bph.15164</article-id><article-id pub-id-type="publisher-id">BPH15164</article-id><article-id pub-id-type="other">2020-BJP-0688-MR.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Mini&#x02010;reviews</subject></subj-group><subj-group subj-group-type="heading"><subject>Mini&#x02010;reviews</subject></subj-group></article-categories><title-group><article-title>Harnessing inflammation resolving&#x02010;based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID&#x02010;19?</article-title><alt-title alt-title-type="left-running-head">Sousa et al.</alt-title></title-group><contrib-group><contrib id="bph15164-cr-0001" contrib-type="author"><name><surname>Sousa</surname><given-names>Lirl&#x000e2;ndia P.</given-names></name><xref ref-type="aff" rid="bph15164-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bph15164-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bph15164-cr-0002" contrib-type="author"><name><surname>Pinho</surname><given-names>Vanessa</given-names></name><xref ref-type="aff" rid="bph15164-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bph15164-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="bph15164-cr-0003" contrib-type="author" corresp="yes"><name><surname>Teixeira</surname><given-names>Mauro M.</given-names></name><xref ref-type="aff" rid="bph15164-aff-0001">
<sup>1</sup>
</xref><address><email>mmtex@icb.ufmg.br</email></address></contrib></contrib-group><aff id="bph15164-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Laboratorio de Imunofamacologia, Departamento de Bioqu&#x000ed;mica e Imunologia, Instituto de Ci&#x000ea;ncias Biol&#x000f3;gicas</named-content>
<institution>Universidade Federal de Minas Gerais</institution>
<city>Belo Horizonte</city>
<country country="BR">Brazil</country>
</aff><aff id="bph15164-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Departamento de An&#x000e1;lises Cl&#x000ed;nicas e Toxicol&#x000f3;gicas, Faculdade de Farm&#x000e1;cia</named-content>
<institution>Universidade Federal de Minas Gerais</institution>
<city>Belo Horizonte</city>
<country country="BR">Brazil</country>
</aff><aff id="bph15164-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Departamento de Morfologia, Instituto de Ci&#x000ea;ncias Biol&#x000f3;gicas</named-content>
<institution>Universidade Federal de Minas Gerais</institution>
<city>Belo Horizonte</city>
<country country="BR">Brazil</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Mauro Martins Teixeira, Departamento de Bioqu&#x000ed;mica e Imunologia, Instituto de Ci&#x000ea;ncias Biol&#x000f3;gicas, Universidade Federal de Minas Gerais, Av. Ant&#x000f4;nio Carlos, 6627 Pampulha, 31270&#x02010;901 Belo Horizonte, MG, Brazil.<break/>
Email: <email>mmtex@icb.ufmg.br</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2020</year></pub-date><volume>177</volume><issue>17</issue><issue-id pub-id-type="doi">10.1111/bph.v177.17</issue-id><fpage>3898</fpage><lpage>3904</lpage><history><date date-type="received"><day>14</day><month>5</month><year>2020</year></date><date date-type="rev-recd"><day>29</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>01</day><month>6</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 The British Pharmacological Society <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 The British Pharmacological Society</copyright-statement></permissions><self-uri content-type="pdf" xlink:href="file:BPH-177-3898.pdf"/><abstract><p>Inflammation is generally accepted as a component of the host defence system and a protective response in the context of infectious diseases. However, altered inflammatory responses can contribute to disease in infected individuals. Many endogenous mediators that drive the resolution of inflammation are now known. Overall, mediators of resolution tend to decrease inflammatory responses and provide normal or greater ability of the host to deal with infection. In the lung, it seems that pro&#x02010;resolution molecules, or strategies that promote their increase, tend to suppress inflammation and lung injury and facilitate control of bacterial or viral burden. Here, we argue that the demonstrated anti&#x02010;inflammatory, pro&#x02010;resolving, anti&#x02010;thrombogenic and anti&#x02010;microbial effects of such endogenous mediators of resolution may be useful in the treatment of the late stages of the disease in patients with COVID&#x02010;19.</p></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institute of Science and Technology </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100002613</institution-id></institution-wrap></funding-source><award-id>465425/2014&#x02010;3</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="0"/><page-count count="7"/><word-count count="5722"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.6 mode:remove_FC converted:17.08.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="bph15164-cit-9001">
<string-name>
<surname>Sousa</surname>
<given-names>LP</given-names>
</string-name>, <string-name>
<surname>Pinho</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Teixeira</surname>
<given-names>MM</given-names>
</string-name>. <article-title>Harnessing inflammation resolving&#x02010;based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID&#x02010;19?</article-title>
<source xml:lang="en">Br J Pharmacol</source>. <year>2020</year>;<volume>177</volume>:<fpage>3898</fpage>&#x02013;<lpage>3904</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15164</pub-id>
</mixed-citation>
</p></notes></front><body id="bph15164-body-0001"><def-list list-content="abbreviations" id="bph15164-lp-0001"><title>Abbreviations</title><def-item><term id="bph15164-li-0001">5&#x02010;LOX</term><def id="bph15164-li-0003"><p>5&#x02010;lipoxygenase</p></def></def-item><def-item><term id="bph15164-li-0004">17&#x02010;HDHA</term><def id="bph15164-li-0005"><p>(4Z,7Z,10Z,13Z,15E,19Z)&#x02010;<italic>17</italic>&#x02010;hydroxydocosa&#x02010;4,7,10,13,15,19&#x02010;hexaenoic acid</p></def></def-item><def-item><term id="bph15164-li-0006">ACE2</term><def id="bph15164-li-0007"><p>Angiotensin&#x02010;converting enzyme 2</p></def></def-item><def-item><term id="bph15164-li-0008">COX&#x02010;2</term><def id="bph15164-li-0009"><p>cyclooxygenase&#x02010;2</p></def></def-item><def-item><term id="bph15164-li-0010">IAV</term><def id="bph15164-li-0011"><p>influenza A virus</p></def></def-item><def-item><term id="bph15164-li-0012">LX</term><def id="bph15164-li-0013"><p>lipoxin</p></def></def-item><def-item><term id="bph15164-li-0014">PDE4</term><def id="bph15164-li-0015"><p>phosphodiesterase type 4</p></def></def-item><def-item><term id="bph15164-li-0016">RSV</term><def id="bph15164-li-0017"><p>respiratory syncytial virus</p></def></def-item></def-list><sec id="bph15164-sec-0001"><label>1</label><title>GENERAL CONSIDERATIONS</title><p>Inflammation is generally accepted as a protective response in the context of infectious diseases (Tavares, Teixeira, &#x00026; Garcia,&#x000a0;<xref rid="bph15164-bib-0040" ref-type="ref">2017</xref>). Indeed, inflammatory responses are necessary to contain microorganisms and to provide the adequate co&#x02010;stimulatory stimuli to adaptive immune responses. Clear examples of these roles are seen in neutropenic individuals who usually die of disseminated bacterial infections (Gustinetti &#x00026; Mikulska,&#x000a0;<xref rid="bph15164-bib-0016" ref-type="ref">2016</xref>). Individuals unable to mount an adequate inflammatory response, such as elderly individuals and those undergoing cancer treatment, frequently fail to respond to vaccines. However, it is also clear that an altered(decreased, misplaced, excessive, systemic, or modified) inflammatory response can contribute to disease in infected individuals (Tavares et al.,&#x000a0;<xref rid="bph15164-bib-0039" ref-type="ref">2016</xref>). Thus, absent or decreased inflammatory responses may lead to microbial spread and death. Bacterial sepsis is a good example of a syndrome where misplaced (systemic rather than at the site of infection), excessive (large amounts of mediators in the circulation), and altered (mediators found in severe disease may be different from those found in less severely affected patients) inflammatory responses occur. We have argued previously that taming this altered inflammatory response may be beneficial in individuals with severe infections (Costa, Fagundes, Souza, &#x00026; Teixeira,&#x000a0;<xref rid="bph15164-bib-0010" ref-type="ref">2013</xref>; Garcia, Guabiraba, Soriani, &#x00026; Teixeira,&#x000a0;<xref rid="bph15164-bib-0014" ref-type="ref">2010</xref>). In this review, we will argue for the potential of utilizing the pathways and mediators of resolution of inflammation, as a means of providing adjunct treatment (to antimicrobial drugs) for severe infectious diseases.</p><p>Resolution of inflammation, in a simplified way, is defined as the period between the peak of granulocyte accumulation in the tissue and the complete clearance of recruited inflammatory cells (Sugimoto, Vago, Perretti, &#x00026; Teixeira,&#x000a0;<xref rid="bph15164-bib-0038" ref-type="ref">2019</xref>) (see Figure&#x000a0;<xref rid="bph15164-fig-0001" ref-type="fig">1</xref>). Fundamentally, resolution of inflammation will contribute to the reversal of the accumulation of granulocytes in the inflammatory site and reprogramme the cellular and molecular response within the tissue, leading to tissue regeneration and repair. However, tissues tend not to return completely to their pre&#x02010;inflamed state, in terms of cellular composition and phenotype, as previously thought, but to a state of &#x0201c;adapted homoeostasis,&#x0201d; which modifies the severity of subsequent inflammatory responses (Feehan &#x00026; Gilroy,&#x000a0;<xref rid="bph15164-bib-0012" ref-type="ref">2019</xref>). Resolution of inflammation is mediated by the endogenous mediators of resolution. These are molecules with very diverse chemical structures that by acting on their corresponding receptors induce a cascade of events (pathways) that lead to the resolution of inflammation and the adapted homoeostasis of tissues (Sugimoto et al.,&#x000a0;<xref rid="bph15164-bib-0038" ref-type="ref">2019</xref>) (Figure&#x000a0;<xref rid="bph15164-fig-0001" ref-type="fig">1</xref>).</p><fig fig-type="FIGURE" xml:lang="en" id="bph15164-fig-0001" orientation="portrait" position="float"><label>FIGURE 1</label><caption><p>The main mediators of the resolution of inflammation and their general functions in the context of inflammation. MCTR: maresin conjugates in tissue regeneration; PCTR: protectin conjugate in tissue regeneration</p></caption><graphic id="nlm-graphic-1" xlink:href="BPH-177-3898-g001"/></fig><p>The possibility of using mediators of resolution to treat inflammation has led to the concept of &#x0201c;resolution pharmacology,&#x0201d; based on correcting and &#x0201c;pushing the resolution back on track&#x0201d; as a new strategy for the treatment of complicated and often chronic, inflammatory diseases, such as rheumatoid arthritis (Perretti, Leroy, Bland, &#x00026; Montero&#x02010;Melendez,&#x000a0;<xref rid="bph15164-bib-0029" ref-type="ref">2015</xref>). There have also been a few studies evaluating the role and effects of mediators of resolution of inflammation in the context of bacterial, viral, and fungal infection. Overall, most studies have suggested that the mediators of resolution tend to decrease inflammatory responses during infection and provide normal or greater ability of the host to deal with infection. For example, in the context of infection with the protozoan parasite <italic>Leishmania brasiliensis</italic>, the pro&#x02010;resolution peptide, annexin A1 (<ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1031">ANXA1</ext-link>), was actively expressed during infection and its absence was associated with more intense inflammatory responses and delayed ability to resolve the lesion (Oliveira et al.,&#x000a0;<xref rid="bph15164-bib-0028" ref-type="ref">2017</xref>). Similarly, <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=23">FPR2/ALX</ext-link>, the receptor for ANXA1, lipoxin A4 (<ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034">LXA<sub>4</sub></ext-link>), and resolvin D1 (<ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934">RvD1</ext-link>), played non&#x02010;redundant roles in sepsis with exacerbated disease severity in the absence of the receptor (Gobbetti et al.,&#x000a0;<xref rid="bph15164-bib-0015" ref-type="ref">2014</xref>). Below, we review the effects of the mediators of resolution in the context of experimental models simulating inflammation and infection in the lungs.</p><sec id="bph15164-sec-0002"><label>1.1</label><title>Effects of pro&#x02010;resolution&#x02010;based strategies for treatment of lung infections</title><p>Several pro&#x02010;resolution molecules have been shown to decrease effectively inflammation and injury in models simulating pulmonary disease, including asthma, fibrosis, and infection. In the context of asthma, local or systemic administration of <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2448">hydrogen peroxide</ext-link> (Reis et al.,&#x000a0;<xref rid="bph15164-bib-0032" ref-type="ref">2015</xref>), <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=582">angiotensin&#x02010;(1&#x02013;7</ext-link>) (Magalhaes et al.,&#x000a0;<xref rid="bph15164-bib-0023" ref-type="ref">2018</xref>), ANXA1(Bandeira&#x02010;Melo et al.,&#x000a0;<xref rid="bph15164-bib-0006" ref-type="ref">2005</xref>), and LXA4 (Levy et al.,&#x000a0;<xref rid="bph15164-bib-0020" ref-type="ref">2007</xref>) all decrease infiltration of eosinophils in the lung and, in general, changes in airway function. Similarly, mediators of resolution decrease inflammation, injury, and fibrosis in bleomycin&#x02010;induced pulmonary fibrosis (Damazo et al.,&#x000a0;<xref rid="bph15164-bib-0011" ref-type="ref">2011</xref>; Rago et al.,&#x000a0;<xref rid="bph15164-bib-0030" ref-type="ref">2019</xref>) and silicosis (Trentin et al.,&#x000a0;<xref rid="bph15164-bib-0041" ref-type="ref">2015</xref>).</p><p>A relatively few studies have examined the effects of the administration of mediators of pro&#x02010;resolution or their genetic absence, in the context of bacterial infection in the lung. For example, administration of the <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=260">PDE4</ext-link> inhibitor <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260">rolipram</ext-link> decreased neutrophil recruitment into the lungs and airways and reduced lung injury in a model of pneumococcal pneumonia. There were also decreased levels of cytokines in the airways, but bacterial burden was not reduced (Tavares et al.,&#x000a0;<xref rid="bph15164-bib-0039" ref-type="ref">2016</xref>). Noteworthy, the combined administration of rolipram and the antibiotic, <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5326">ceftriaxone</ext-link>, improved survival in pneumococcal pneumonia by decreasing inflammation, lung injury, bacterial burden, and phagocytosis. The effects of rolipram appeared to be due to the increase in local levels of ANXA1 (Tavares et al.,&#x000a0;<xref rid="bph15164-bib-0039" ref-type="ref">2016</xref>). This is in agreement with our studies suggesting that ANXA1 mediated the pro&#x02010;resolution properties of <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352">cAMP</ext-link>&#x02010;elevating agents and cAMP&#x02010;mimetic drugs (Lima et al.,&#x000a0;<xref rid="bph15164-bib-0021" ref-type="ref">2017</xref>). Interestingly, AnxA1 and Fpr2 KO mice were highly susceptible to pneumococcal pneumonia, displaying uncontrolled inflammation, increased bacterial dissemination, loss of lung barrier integrity, and pulmonary dysfunction. Moreover, treatment with the ANXA1 peptidomimetic, <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1044">annexin 1&#x02010;(2&#x02013;26)</ext-link> decreased inflammation, lung damage, and bacterial burden in the airways by increasing macrophage phagocytosis (Machado et al.,&#x000a0;<xref rid="bph15164-bib-0022" ref-type="ref">2020</xref>). Similarly, the absence of <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/DatabaseSearchForward?searchString=GPR43%2B%26searchCategories=all%26species=none%26type=all%26comments=includeComments%26order=rank%26submit=Search%2BDatabase">FFA2 receptor</ext-link>s (also known as GPR43; a receptor for short&#x02010;chain fatty acids) led to increased susceptibility to <styled-content style="fixed-case" toggle="no"><italic>Klebsiella pneumoniae</italic></styled-content> infection, which was associated with both uncontrolled proliferation of bacteria and increased inflammatory response. Treatment with another FFA2 receptor ligand, acetate, was protective during bacterial lung infection (Galv&#x000e3;o et al.,&#x000a0;<xref rid="bph15164-bib-0013" ref-type="ref">2018</xref>). Early treatment with the aspirin&#x02010;induced resolvin, <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6239">AT&#x02010;RvD1</ext-link> enhanced clearance of <styled-content style="fixed-case" toggle="no"><italic>Escherichia coli</italic></styled-content> and <styled-content style="fixed-case" toggle="no"><italic>Pseudomonas aeruginosa</italic></styled-content> in vivo. This was associated with enhanced phagocytosis of bacterial particles and accelerated neutrophil clearance during pneumonia in vivo (Abdulnour et al.,&#x000a0;<xref rid="bph15164-bib-0001" ref-type="ref">2016</xref>). Therefore, it seems that treatment with pro&#x02010;resolution molecules or strategies that promote their increase (such as cAMP elevating agents) tend to decrease inflammation and lung injury and facilitate microbial control following bacterial infection. It remains to be determined whether this is valid for all pro&#x02010;resolution molecules, their comparative efficacies, and whether there is synergy when more than one agent is used.</p><p>A few studies have also evaluated the relevance of pro&#x02010;resolution molecules and pathways in the context of viral infections of the lung, especially influenza. In an elegant study, Morita et al.&#x000a0;(<xref rid="bph15164-bib-0025" ref-type="ref">2013</xref>) found that another endogenous mediator of resolution, the lipid protectin D1 (PD1), was suppressed during severe influenza, and PD1 levels inversely correlated with the pathogenicity of H5N1 viruses (Morita et al.,&#x000a0;<xref rid="bph15164-bib-0025" ref-type="ref">2013</xref>). PD1 treatment improved the survival and pulmonary injury following severe influenza in mice and markedly attenuated influenza virus replication via the RNA export machinery. This is consistent with an earlier finding showing that a strain of H5N1 (VN/1203) was more pathogenic in mice than H1N1 (1918 pandemic virus), in part due to early and sustained up&#x02010;regulation of the components of pro&#x02010;inflammatory molecules along with inhibition of lipoxin&#x02010;mediated anti&#x02010;inflammatory responses (Cilloniz et al.,&#x000a0;<xref rid="bph15164-bib-0009" ref-type="ref">2010</xref>). The influenza A virus (IAV) H1N1 (strain PR8) enhanced its replication and propagation through the use of the ANXA1/FPR2 axis (Ampomah, Moraes, Lukman, &#x00026; Lim,&#x000a0;<xref rid="bph15164-bib-0004" ref-type="ref">2018</xref>; Arora et al.,&#x000a0;<xref rid="bph15164-bib-0005" ref-type="ref">2016</xref>). Indeed, the latter study clearly shows that regulation of ANXA1 and FPR2 expression during IAV infection may be a viral strategy to enhance its infectivity. However, administration of ANXA1 to mice, prior to infection, with the same strain of IAV, significantly attenuated pulmonary injury induced by the infection, with significantly improved survival, impaired viral replication in the respiratory tract, and less severe lung damage. These effects were associated with expansion of alveolar macrophages in ANXA1 pretreated animals (Schloer et al.,&#x000a0;<xref rid="bph15164-bib-0033" ref-type="ref">2019</xref>).</p><p>At least one study has evaluated the role of pro&#x02010;resolution molecules in the context of pulmonary viral infections other than influenza. Infection of <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1385">5&#x02010;lipoxygenase (5&#x02010;LOX</ext-link>)&#x02010;deficient mice with respiratory syncytial virus (RSV) resulted in enhanced lung pathology. The 5&#x02010;LOX pathway, probably through the production of LXA4 and <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3333">resolvin E1</ext-link> (RvE1), appeared to be necessary for the induction of alternatively activated macrophages and induction of bronchiolitis (Shirey et al.,&#x000a0;<xref rid="bph15164-bib-0035" ref-type="ref">2014</xref>). Interestingly, the specialized pro&#x02010;resolution lipid, 17&#x02010;HDHA, increased the humoral response and provided greater protective effect against live H1N1 influenza infection in mice, thus demonstrating a biological link between pro&#x02010;resolution signals and the adaptive immune system (Ramon et al.,&#x000a0;<xref rid="bph15164-bib-0031" ref-type="ref">2014</xref>). Indeed, the lipoxin <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216">LXB<sub>4</sub></ext-link> was shown to boost memory B&#x02010;cell activation through <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376">COX&#x02010;2</ext-link> to serve as a potential vaccine adjuvant (Kim et al.,&#x000a0;<xref rid="bph15164-bib-0018" ref-type="ref">2018</xref>).</p><p>A previous influenza infection is known to increase the risk to a subsequent pulmonary bacterial infection, such as that caused by <styled-content style="fixed-case" toggle="no">S. pneumoniae</styled-content>. Indeed, post&#x02010;influenza bacterial infections seem to account for a significant number of deaths following annual flu epidemics. In a model of pulmonary co&#x02010;infection with influenza H3N2 (strain A/HKx31) and <styled-content style="fixed-case" toggle="no">S. pneumoniae</styled-content>, Wang et al.&#x000a0;(<xref rid="bph15164-bib-0043" ref-type="ref">2017</xref>) showed that administration of exogenous resolvin AT&#x02010;RvD1, facilitated more rapid clearance of pneumococci in the lungs, while concurrently reducing the severity of pneumonia by limiting excessive leukocyte chemotaxis from the infected bronchioles to distal areas of the lungs (Wang et al.,&#x000a0;<xref rid="bph15164-bib-0043" ref-type="ref">2017</xref>). More recently, we showed that perturbation of the gut microbiota during IAV infection favoured respiratory bacterial superinfection with <styled-content style="fixed-case" toggle="no">S. pneumoniae</styled-content>. In mechanistic terms, reduced production of the predominant short chain fatty acid, <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology%26ligandId=1058">acetate</ext-link>, appeared to account for the facilitating effects of influenza infection. Indeed, treatment with acetate reduced bacterial loads, lung pathology, and improved survival rates of double&#x02010;infected mice (Sencio et al.,&#x000a0;<xref rid="bph15164-bib-0034" ref-type="ref">2020</xref>). It is clear that the overall effects of mediators of resolution in the context of pulmonary infection is enhancement of anti&#x02010;bacterial and anti&#x02010;viral defences and inhibition of inflammatory responses, without interfering with the ability of the host to deal with the infection. A note of caution must be given here. At least one study has shown that resolution of inflammation can trigger a prolonged phase of localized immunosuppression which could predispose the host to secondary infections (Newson et al.,&#x000a0;<xref rid="bph15164-bib-0026" ref-type="ref">2017</xref>).</p></sec><sec id="bph15164-sec-0003"><label>1.2</label><title>COVID&#x02010;19 and the resolution of inflammation</title><p>Since the end of 2019, the world has been swept by the pandemic caused by SARS&#x02010;CoV&#x02010;2, a new coronavirus first detected in China. SARS&#x02010;CoV&#x02010;2 infection causes a disease named COVID&#x02010;19, whose major clinical presentation is pulmonary inflammation and injury. As with most viral infections, the disease is characterized by an initial phase with significant viral replication that is followed by an inflammatory phase. In contrast to many other viral infections of the lung, COVID&#x02010;19 is characterized by significant systemic inflammation (cytokine storm) and damage to organs other than the lung, including the heart and kidney. There is also a significant coagulopathy (Moore et al.,&#x000a0;<xref rid="bph15164-bib-0024" ref-type="ref">2020</xref>). While targeting the virus directly is the rational approach during the first stage of COVID&#x02010;19, regulating the host response during the phase of over&#x02010;exuberant inflammation and excessive coagulation may offer new therapeutic opportunities. Because of their known protective roles in the context of other pulmonary infections, we argue that harnessing pro&#x02010;resolution&#x02010;based therapies may provide unique new treatment strategies in the context of COVID&#x02010;19.</p><p>As shown in Figure&#x000a0;<xref rid="bph15164-fig-0002" ref-type="fig">2</xref>, there are many demonstrated effects of mediators of pro&#x02010;resolution that may be useful in the context of COVID&#x02010;19, including the decrease of neutrophil recruitment and activation, enhancement of pathogen clearance and prevention of excessive coagulation. Patients who recovered from disease had up&#x02010;regulation of ANXA1 in peripheral blood monocytes (Wen et al.,&#x000a0;<xref rid="bph15164-bib-0044" ref-type="ref">2020</xref>), suggesting a counter&#x02010;regulation of the inflammatory response in those patients who survived and could be considered as &#x0201c;well&#x02010;responders&#x0201d;. Although these data remain to be validated in bigger cohorts by measuring the ANXA1 levels in those patients, these initial data suggest that decreased expression of ANXA1 and, potentially, of other pro&#x02010;resolution molecules, may have contributed to worse outcomes in patients with severe COVID&#x02010;19.</p><fig fig-type="FIGURE" xml:lang="en" id="bph15164-fig-0002" orientation="portrait" position="float"><label>FIGURE 2</label><caption><p>Effects of pro&#x02010;resolution&#x02010;based therapies in pulmonary infections. Created with <ext-link ext-link-type="uri" xlink:href="http://Biorender.com">Biorender.com</ext-link>
</p></caption><graphic id="nlm-graphic-3" xlink:href="BPH-177-3898-g002"/></fig><p>Three molecules with demonstrated pro&#x02010;resolving activity may be especially useful in the context of COVID&#x02010;19&#x02014;ANXA1, angiotensin&#x02010;(1&#x02013;7), and plasmin &#x02013; and these are now discussed in greater detail. For the first, expression of the <italic>AnxA1</italic> gene was increased in mice recovering from pneumococcal infection (Tavares et al.,&#x000a0;<xref rid="bph15164-bib-0039" ref-type="ref">2016</xref>) and administration of the ANXA1 peptidomimetic improved severe pneumococcal pneumonia (Machado et al.,&#x000a0;<xref rid="bph15164-bib-0022" ref-type="ref">2020</xref>) and severe influenza. Together with data showing increased expression in recovered COVID&#x02010;19 patients, these data suggest that restoration of ANXA1 levels may be useful to treat severe COVID&#x02010;19 patients.</p><p>The cell surface protein, <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614">angiotensin converting emzyme&#x02010;2 (ACE2)</ext-link> appears to be the most important receptor for SARS&#x02010;CoV&#x02010;2 to enter cells. This enzyme generates angiotensin&#x02010;(1&#x02013;7), an endogenous pro&#x02010;resolution mediator (Barroso et al.,&#x000a0;<xref rid="bph15164-bib-0007" ref-type="ref">2017</xref>; Magalhaes et al.,&#x000a0;<xref rid="bph15164-bib-0023" ref-type="ref">2018</xref>). We have shown that Ang&#x02010;(1&#x02013;7) exerted pro&#x02010;resolving actions during lung inflammation (Magalhaes et al.,&#x000a0;<xref rid="bph15164-bib-0023" ref-type="ref">2018</xref>) and was protective in kidney, heart, and lung diseases (see Sim&#x000f5;es E Silva, Silveira, Ferreira, &#x00026; Teixeira,&#x000a0;<xref rid="bph15164-bib-0036" ref-type="ref">2013</xref>). Indeed, reduced levels of <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614">ACE2</ext-link> increased SARS&#x02010;CoV&#x02010;induced lung injury by re&#x02010;directing the renin&#x02010;angiotensin system away from the ACE2/Ang&#x02010;(1&#x02013;7) regulatory and protective pathway towards the pro&#x02010;inflammatory <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504">angiotensin II</ext-link> &#x02010;<ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=34">AT<sub>1</sub></ext-link> receptor pathway. The effects of this re&#x02010;direction were attenuated by blocking the AT<sub>1</sub> receptors (Kuba et al.,&#x000a0;<xref rid="bph15164-bib-0019" ref-type="ref">2005</xref>). It remains to be tested whether this pathway is defective in the context of COVID&#x02010;19 and whether the activation of the protective axis by administering the Ang&#x02010;(1&#x02013;7) peptide or inhibiting the pro&#x02010;inflammatory pathways by blocking AT<sub>1</sub> receptors will constitute a protective approach to control the effects of COVID&#x02010;19.</p><p>An excessive coagulation response, which is also observed in patients with sepsis, shown by enhanced clot formation and suppression or consumption of fibrinolytic factors is an important characteristic of COVID&#x02010;19 patients (Moore et al.,&#x000a0;<xref rid="bph15164-bib-0024" ref-type="ref">2020</xref>). In this regard, we have shown that plasmin, a fibrinolytic protein, can promote resolution of inflammation (Sugimoto et al.,&#x000a0;<xref rid="bph15164-bib-0037" ref-type="ref">2017</xref>). SARS&#x02010;CoV&#x02010;2 induces the macrophage activation syndrome that can be targeted by the cell reprogramming actions of <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2394">plasminogen</ext-link>/plasmin (Sugimoto et al.,&#x000a0;<xref rid="bph15164-bib-0037" ref-type="ref">2017</xref>; Vago et al.,&#x000a0;<xref rid="bph15164-bib-0042" ref-type="ref">2019</xref>). Indeed, patients with severe COVID&#x02010;19, treated with inhalation of atomized, freeze&#x02010;dried plasminogen demonstrated improved lung lesions and hypoxia (Wu et al.,&#x000a0;<xref rid="bph15164-bib-0045" ref-type="ref">2020</xref>). During physiological coagulation, there is up&#x02010;regulation of a group of lipid mediators of resolution that enhanced leukocyte antimicrobial responses (Norris, Libreros, Chiang, &#x00026; Serhan,&#x000a0;<xref rid="bph15164-bib-0027" ref-type="ref">2017</xref>). Administration of one of these mediators, the resolvin, RvD4, attenuated the severity of pathological thrombosis (Cherpokova et al.,&#x000a0;<xref rid="bph15164-bib-0008" ref-type="ref">2019</xref>). Therefore, by exploring the properties of pro&#x02010;resolution mediators, such as plasmin, we may in the future provide better control of several crucial features of COVID&#x02010;19, such as the hyperinflammatory response, coagulation and tissue damage.</p></sec></sec><sec id="bph15164-sec-0004"><label>2</label><title>CONCLUDING REMARKS</title><p>The development of drugs targeting viral replication and entry is the rational therapy for the early stages of COVID&#x02010;19disease but may not be as useful at the advanced stages of the infection. Recently, the term resolution pharmacology (Perretti et al.,&#x000a0;<xref rid="bph15164-bib-0029" ref-type="ref">2015</xref>) was proposed to describe therapeutic strategies that explore the activation of endogenous pathways of resolution, through novel resolution&#x02010;based therapeutic agents. Pharmacological induction of resolution of inflammation, rather than anti&#x02010;inflammation therapies, do not cause immunosuppression and are a promising tool to treat the consequences of infectious diseases (Figure&#x000a0;<xref rid="bph15164-fig-0002" ref-type="fig">2</xref>), at least, as adjunct therapy. As discussed here, several pro&#x02010;resolution molecules exhibit a marked capacity to clear viral or bacterial infections and cellular debris, adding to their anti&#x02010;inflammatory and pro&#x02010;resolution abilities. The future of this expanding field shows great promise and requires further validation to prove the concept that pro&#x02010;resolution&#x02010;based therapies are a more effective approach than anti&#x02010;inflammatory therapies, to treat over&#x02010;exuberant inflammation arising from infectious diseases, including COVID&#x02010;19.</p><sec id="bph15164-sec-0005"><label>2.1</label><title>Nomenclature of targets and ligands</title><p>Key protein targets and ligands in this article are hyperlinked to corresponding entries in <ext-link ext-link-type="uri" xlink:href="http://www.guidetopharmacology.org">http://www.guidetopharmacology.org</ext-link>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al.,&#x000a0;<xref rid="bph15164-bib-0017" ref-type="ref">2018</xref>), and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander, Christopoulos et al.,&#x000a0;<xref rid="bph15164-bib-0002" ref-type="ref">2019</xref>; Alexander, Fabbro et al.,&#x000a0;<xref rid="bph15164-bib-0003" ref-type="ref">2019</xref>).</p></sec></sec><sec sec-type="COI-statement" id="bph15164-sec-0106"><title>CONFLICTS OF INTEREST</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="bph15164-sec-0006"><title>ACKNOWLEDGEMENTS</title><p>Work in our laboratories is funded by the National Institute of Science and Technology in Dengue and host&#x02010;microbial interactions, a programme grant (465425/2014&#x02010;3) from Funda&#x000e7;&#x000e3;o do Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG, Brazil), Coordena&#x000e7;&#x000e3;o de Apoio ao Ensino de Pessoal de Nivel Superior (CAPES, Brazil), and Conselho Nacional de Ensino e Pesquisa (CNPq, Brazil).</p></ack><ref-list id="bph15164-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="bph15164-bib-0001"><mixed-citation publication-type="journal" id="bph15164-cit-0002">
<string-name>
<surname>Abdulnour</surname>, <given-names>R. E.</given-names>
</string-name>, <string-name>
<surname>Sham</surname>, <given-names>H. P.</given-names>
</string-name>, <string-name>
<surname>Douda</surname>, <given-names>D. N.</given-names>
</string-name>, <string-name>
<surname>Colas</surname>, <given-names>R. A.</given-names>
</string-name>, <string-name>
<surname>Dalli</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Bai</surname>, <given-names>Y.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Levy</surname>, <given-names>B. D.</given-names>
</string-name> (<year>2016</year>). <article-title>Aspirin&#x02010;triggered resolvin D1 is produced during self&#x02010;resolving gram&#x02010;negative bacterial pneumonia and regulates host immune responses for the resolution of lung inflammation</article-title>. <source xml:lang="en">Mucosal Immunology</source>, <volume>9</volume>(<issue>5</issue>), <fpage>1278</fpage>&#x02013;<lpage>1287</lpage>. <pub-id pub-id-type="doi">10.1038/mi.2015.129</pub-id>
<pub-id pub-id-type="pmid">26647716</pub-id></mixed-citation></ref><ref id="bph15164-bib-0002"><mixed-citation publication-type="journal" id="bph15164-cit-0003">
<string-name>
<surname>Alexander</surname>, <given-names>S. P. H.</given-names>
</string-name>, <string-name>
<surname>Christopoulos</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Davenport</surname>, <given-names>A. P.</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Mathie</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Peters</surname>, <given-names>J. A.</given-names>
</string-name>, &#x02026; 
<collab collab-type="authors">CGTP Collaborators</collab>
. (<year>2019</year>). <article-title>THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein&#x02010;coupled receptors</article-title>. <source xml:lang="en">British Journal of Pharmacology</source>, <volume>176</volume>, <fpage>S21</fpage>&#x02013;<lpage>S141</lpage>. <pub-id pub-id-type="doi">10.1111/bph.14748</pub-id>
<pub-id pub-id-type="pmid">31710717</pub-id></mixed-citation></ref><ref id="bph15164-bib-0003"><mixed-citation publication-type="journal" id="bph15164-cit-0004">
<string-name>
<surname>Alexander</surname>, <given-names>S. P. H.</given-names>
</string-name>, <string-name>
<surname>Fabbro</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Mathie</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Peters</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Veale</surname>, <given-names>E. L.</given-names>
</string-name>, &#x02026; 
<collab collab-type="authors">CGTP Collaborators</collab>
. (<year>2019</year>). <article-title>THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes</article-title>. <source xml:lang="en">British Journal of Pharmacology</source>, <volume>176</volume>, <fpage>S297</fpage>&#x02013;<lpage>S396</lpage>. <pub-id pub-id-type="doi">10.1111/bph.14752</pub-id>
<pub-id pub-id-type="pmid">31710714</pub-id></mixed-citation></ref><ref id="bph15164-bib-0004"><mixed-citation publication-type="journal" id="bph15164-cit-0005">
<string-name>
<surname>Ampomah</surname>, <given-names>P. B.</given-names>
</string-name>, <string-name>
<surname>Moraes</surname>, <given-names>L. A.</given-names>
</string-name>, <string-name>
<surname>Lukman</surname>, <given-names>H. M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Lim</surname>, <given-names>L. H. K.</given-names>
</string-name> (<year>2018</year>). <article-title>Formyl peptide receptor 2 is regulated by RNA mimics and viruses through an IFN&#x02010;b&#x02010;STAT3&#x02010;dependent pathway</article-title>. <source xml:lang="en">FASEB Journal</source>, <volume>32</volume>(<issue>3</issue>), <fpage>1468</fpage>&#x02013;<lpage>1478</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201700584RR</pub-id>
<pub-id pub-id-type="pmid">29127186</pub-id></mixed-citation></ref><ref id="bph15164-bib-0005"><mixed-citation publication-type="journal" id="bph15164-cit-0006">
<string-name>
<surname>Arora</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Lim</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Bist</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Perumalsamy</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Lukman</surname>, <given-names>H. M.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>F.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Lim</surname>, <given-names>L. H. K.</given-names>
</string-name> (<year>2016</year>). <article-title>Influenza A virus enhances its propagation through the modulation of Annexin&#x02010;A1 dependent endosomal trafficking and apoptosis</article-title>. <source xml:lang="en">Cell Death and Differentiation</source>, <volume>23</volume>(<issue>7</issue>), <fpage>1243</fpage>&#x02013;<lpage>1256</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2016.19</pub-id>
<pub-id pub-id-type="pmid">26943321</pub-id></mixed-citation></ref><ref id="bph15164-bib-0006"><mixed-citation publication-type="journal" id="bph15164-cit-0007">
<string-name>
<surname>Bandeira&#x02010;Melo</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Bonavita</surname>, <given-names>A. G. C.</given-names>
</string-name>, <string-name>
<surname>Diaz</surname>, <given-names>B. L.</given-names>
</string-name>, <string-name>
<surname>Silva</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>e Silva</surname>, <given-names>P. M. R.</given-names>
</string-name>, <string-name>
<surname>Carvalho</surname>, <given-names>V. F.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Martins</surname>, <given-names>M. A.</given-names>
</string-name> (<year>2005</year>). <article-title>A novel effect for annexin 1&#x02010;derived peptide Ac2&#x02010;26: Reduction of allergic inflammation in the rat</article-title>. <source xml:lang="en">The Journal of Pharmacology and Experimental Therapeutics</source>, <volume>313</volume>, <fpage>1416</fpage>&#x02013;<lpage>1422</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.104.080473</pub-id>
<pub-id pub-id-type="pmid">15784654</pub-id></mixed-citation></ref><ref id="bph15164-bib-0007"><mixed-citation publication-type="journal" id="bph15164-cit-0008">
<string-name>
<surname>Barroso</surname>, <given-names>L. C.</given-names>
</string-name>, <string-name>
<surname>Magalhaes</surname>, <given-names>G. S.</given-names>
</string-name>, <string-name>
<surname>Galv&#x000e3;o</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Reis</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Souza</surname>, <given-names>D. G.</given-names>
</string-name>, <string-name>
<surname>Sousa</surname>, <given-names>L. P.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Teixeira</surname>, <given-names>M. M.</given-names>
</string-name> (<year>2017</year>). <article-title>Angiotensin&#x02010;(1&#x02010;7) promotes resolution of neutrophilic inflammation in a model of antigen&#x02010;induced arthritis in mice</article-title>. <source xml:lang="en">Frontiers in Immunology</source>, <volume>8</volume>(<issue>NOV</issue>). <pub-id pub-id-type="doi">10.3389/fimmu.2017.01596</pub-id>
</mixed-citation></ref><ref id="bph15164-bib-0008"><mixed-citation publication-type="journal" id="bph15164-cit-0009">
<string-name>
<surname>Cherpokova</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Jouvene</surname>, <given-names>C. C.</given-names>
</string-name>, <string-name>
<surname>Libreros</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>DeRoo</surname>, <given-names>E. P.</given-names>
</string-name>, <string-name>
<surname>Chu</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>De La Rosa</surname>, <given-names>X.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Serhan</surname>, <given-names>C. N.</given-names>
</string-name> (<year>2019</year>). <article-title>Resolvin D4 attenuates the severity of pathological thrombosis in mice</article-title>. <source xml:lang="en">Blood</source>, <volume>134</volume>(<issue>17</issue>), <fpage>1458</fpage>&#x02013;<lpage>1468</lpage>. <pub-id pub-id-type="doi">10.1182/blood.2018886317</pub-id>
<pub-id pub-id-type="pmid">31300403</pub-id></mixed-citation></ref><ref id="bph15164-bib-0009"><mixed-citation publication-type="journal" id="bph15164-cit-0010">
<string-name>
<surname>Cilloniz</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Pantin&#x02010;Jackwood</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Ni</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Goodman</surname>, <given-names>A. G.</given-names>
</string-name>, <string-name>
<surname>Peng</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Proll</surname>, <given-names>S. C.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Katze</surname>, <given-names>M. G.</given-names>
</string-name> (<year>2010</year>). <article-title>Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection</article-title>. <source xml:lang="en">Journal of Virology</source>, <volume>84</volume>(<issue>15</issue>), <fpage>7613</fpage>&#x02013;<lpage>7624</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.00553-10</pub-id>
<pub-id pub-id-type="pmid">20504916</pub-id></mixed-citation></ref><ref id="bph15164-bib-0010"><mixed-citation publication-type="journal" id="bph15164-cit-0011">
<string-name>
<surname>Costa</surname>, <given-names>V. V.</given-names>
</string-name>, <string-name>
<surname>Fagundes</surname>, <given-names>C. T.</given-names>
</string-name>, <string-name>
<surname>Souza</surname>, <given-names>D. G.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Teixeira</surname>, <given-names>M. M.</given-names>
</string-name> (<year>2013</year>). <article-title>Inflammatory and innate immune responses in dengue infection: Protection versus disease induction</article-title>. <source xml:lang="en">The American Journal of Pathology</source>, <volume>182</volume>, <fpage>1950</fpage>&#x02013;<lpage>1961</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2013.02.027</pub-id>
<pub-id pub-id-type="pmid">23567637</pub-id></mixed-citation></ref><ref id="bph15164-bib-0011"><mixed-citation publication-type="journal" id="bph15164-cit-0012">
<string-name>
<surname>Damazo</surname>, <given-names>A. S.</given-names>
</string-name>, <string-name>
<surname>Sampaio</surname>, <given-names>A. L. F.</given-names>
</string-name>, <string-name>
<surname>Nakata</surname>, <given-names>C. M. A. G.</given-names>
</string-name>, <string-name>
<surname>Flower</surname>, <given-names>R. J.</given-names>
</string-name>, <string-name>
<surname>Perretti</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Oliani</surname>, <given-names>S. M.</given-names>
</string-name> (<year>2011</year>). <article-title>Endogenous annexin A1 counter&#x02010;regulates bleomycin&#x02010;induced lung fibrosis</article-title>. <source xml:lang="en">BMC Immunology</source>, <volume>12</volume>, <fpage>59</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2172-12-59</pub-id>
<pub-id pub-id-type="pmid">22011168</pub-id></mixed-citation></ref><ref id="bph15164-bib-0012"><mixed-citation publication-type="journal" id="bph15164-cit-0013">
<string-name>
<surname>Feehan</surname>, <given-names>K. T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Gilroy</surname>, <given-names>D. W.</given-names>
</string-name> (<year>2019</year>). <article-title>Is resolution the end of inflammation?</article-title>
<source xml:lang="en">Trends in Molecular Medicine</source>, <volume>25</volume>, <fpage>198</fpage>&#x02013;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2019.01.006</pub-id>
<pub-id pub-id-type="pmid">30795972</pub-id></mixed-citation></ref><ref id="bph15164-bib-0013"><mixed-citation publication-type="journal" id="bph15164-cit-0014">
<string-name>
<surname>Galv&#x000e3;o</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Tavares</surname>, <given-names>L. P.</given-names>
</string-name>, <string-name>
<surname>Corr&#x000ea;a</surname>, <given-names>R. O.</given-names>
</string-name>, <string-name>
<surname>Fachi</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Rocha</surname>, <given-names>V. M.</given-names>
</string-name>, <string-name>
<surname>Rungue</surname>, <given-names>M.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Vieira</surname>, <given-names>A. T.</given-names>
</string-name> (<year>2018</year>). <article-title>The metabolic sensor GPR43 receptor plays a role in the control of Klebsiella pneumoniae infection in the lung</article-title>. <source xml:lang="en">Frontiers in Immunology</source>, <volume>9</volume>(<issue>FEB</issue>), <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00142</pub-id>
<pub-id pub-id-type="pmid">29403488</pub-id></mixed-citation></ref><ref id="bph15164-bib-0014"><mixed-citation publication-type="journal" id="bph15164-cit-0015">
<string-name>
<surname>Garcia</surname>, <given-names>C. C.</given-names>
</string-name>, <string-name>
<surname>Guabiraba</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Soriani</surname>, <given-names>F. M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Teixeira</surname>, <given-names>M. M.</given-names>
</string-name> (<year>2010</year>). <article-title>The development of anti&#x02010;inflammatory drugs for infectious diseases</article-title>. <source xml:lang="en">Discovery Medicine</source>, <volume>10</volume>(<issue>55</issue>), <fpage>479</fpage>&#x02013;<lpage>488</lpage>.<pub-id pub-id-type="pmid">21189219</pub-id></mixed-citation></ref><ref id="bph15164-bib-0015"><mixed-citation publication-type="journal" id="bph15164-cit-0016">
<string-name>
<surname>Gobbetti</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Coldewey</surname>, <given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>McArthur</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Le Faouder</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Cenac</surname>, <given-names>N.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Perretti</surname>, <given-names>M.</given-names>
</string-name> (<year>2014</year>). <article-title>Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis</article-title>. <source xml:lang="en">Proceedings of the National Academy of Sciences of the United States of America</source>, <volume>111</volume>, <fpage>18685</fpage>&#x02013;<lpage>18690</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1410938111</pub-id>
<pub-id pub-id-type="pmid">25512512</pub-id></mixed-citation></ref><ref id="bph15164-bib-0016"><mixed-citation publication-type="journal" id="bph15164-cit-0017">
<string-name>
<surname>Gustinetti</surname>, <given-names>G.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Mikulska</surname>, <given-names>M.</given-names>
</string-name> (<year>2016</year>). <article-title>Bloodstream infections in neutropenic cancer patients: A practical update</article-title>. <source xml:lang="en">Virulence</source>, <volume>7</volume>, <fpage>280</fpage>&#x02013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1080/21505594.2016.1156821</pub-id>
<pub-id pub-id-type="pmid">27002635</pub-id></mixed-citation></ref><ref id="bph15164-bib-0017"><mixed-citation publication-type="journal" id="bph15164-cit-0018">
<string-name>
<surname>Harding</surname>, <given-names>S. D.</given-names>
</string-name>, <string-name>
<surname>Sharman</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Faccenda</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Southan</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Pawson</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Ireland</surname>, <given-names>S.</given-names>
</string-name>, &#x02026; 
<collab collab-type="authors">NC&#x02010;IUPHAR</collab>
. (<year>2018</year>). <article-title>The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY</article-title>. <source xml:lang="en">Nucleic Acids Research</source>, <volume>46</volume>, <fpage>D1091</fpage>&#x02013;<lpage>D1106</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx1121</pub-id>
<pub-id pub-id-type="pmid">29149325</pub-id></mixed-citation></ref><ref id="bph15164-bib-0018"><mixed-citation publication-type="journal" id="bph15164-cit-0019">
<string-name>
<surname>Kim</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Lannan</surname>, <given-names>K. L.</given-names>
</string-name>, <string-name>
<surname>Thatcher</surname>, <given-names>T. H.</given-names>
</string-name>, <string-name>
<surname>Pollock</surname>, <given-names>S. J.</given-names>
</string-name>, <string-name>
<surname>Woeller</surname>, <given-names>C. F.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Phipps</surname>, <given-names>R. P.</given-names>
</string-name> (<year>2018</year>). <article-title>Lipoxin B4 enhances human memory B cell antibody production via upregulating cyclooxygenase&#x02010;2 expression</article-title>. <source xml:lang="en">The Journal of Immunology.</source>, <volume>201</volume>, <fpage>3343</fpage>&#x02013;<lpage>3351</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1700503</pub-id>
<pub-id pub-id-type="pmid">30348736</pub-id></mixed-citation></ref><ref id="bph15164-bib-0019"><mixed-citation publication-type="journal" id="bph15164-cit-0020">
<string-name>
<surname>Kuba</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Imai</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Rao</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Gao</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Guo</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Guan</surname>, <given-names>B.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Penninger</surname>, <given-names>J. M.</given-names>
</string-name> (<year>2005</year>). <article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus&#x02010;induced lung injury</article-title>. <source xml:lang="en">Nature Medicine</source>, <volume>11</volume>(<issue>8</issue>), <fpage>875</fpage>&#x02013;<lpage>879</lpage>. <pub-id pub-id-type="doi">10.1038/nm1267</pub-id>
</mixed-citation></ref><ref id="bph15164-bib-0020"><mixed-citation publication-type="journal" id="bph15164-cit-0021">
<string-name>
<surname>Levy</surname>, <given-names>B. D.</given-names>
</string-name>, <string-name>
<surname>Lukacs</surname>, <given-names>N. W.</given-names>
</string-name>, <string-name>
<surname>Berlin</surname>, <given-names>A. A.</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Guilford</surname>, <given-names>W. J.</given-names>
</string-name>, <string-name>
<surname>Serhan</surname>, <given-names>C. N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Parkinson</surname>, <given-names>J. F.</given-names>
</string-name> (<year>2007</year>). <article-title>Lipoxin A<sub>4</sub> stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism</article-title>. <source xml:lang="en">The FASEB Journal.</source>, <volume>21</volume>, <fpage>3877</fpage>&#x02013;<lpage>3884</lpage>. <pub-id pub-id-type="doi">10.1096/fj.07-8653com</pub-id>
<pub-id pub-id-type="pmid">17625069</pub-id></mixed-citation></ref><ref id="bph15164-bib-0021"><mixed-citation publication-type="journal" id="bph15164-cit-0022">
<string-name>
<surname>Lima</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Vago</surname>, <given-names>J. P.</given-names>
</string-name>, <string-name>
<surname>Caux</surname>, <given-names>T. R.</given-names>
</string-name>, <string-name>
<surname>Negreiros&#x02010;Lima</surname>, <given-names>G. L.</given-names>
</string-name>, <string-name>
<surname>Sugimoto</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Tavares</surname>, <given-names>L. P.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Sousa</surname>, <given-names>L. P.</given-names>
</string-name> (<year>2017</year>). <article-title>The resolution of acute inflammation induced by cyclic AMP is dependent on Annexin A1</article-title>. <source xml:lang="en">The Journal of Biological Chemistry</source>, <volume>292</volume>, <fpage>13758</fpage>&#x02013;<lpage>13773</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m117.800391</pub-id>
<pub-id pub-id-type="pmid">28655761</pub-id></mixed-citation></ref><ref id="bph15164-bib-0022"><mixed-citation publication-type="journal" id="bph15164-cit-0023">
<string-name>
<surname>Machado</surname>, <given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>P&#x000e1;dua</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Geovanna</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Souza</surname>, <given-names>V. S.</given-names>
</string-name>, <string-name>
<surname>Fernando</surname>, <given-names>C. M. Q.</given-names>
</string-name>, <string-name>
<surname>Ascen&#x000e7;&#x000e3;o</surname>, <given-names>R.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Sousa</surname>, <given-names>L. P.</given-names>
</string-name> (<year>2020</year>). <article-title>The Annexin A1/FPR2 pathway controls the inflammatory response and bacterial dissemination in experimental pneumococcal pneumonia</article-title>. <source xml:lang="en">The FASEB Journal</source>, <volume>34</volume>(<issue>August 2019</issue>), <fpage>2749</fpage>&#x02013;<lpage>2764</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201902172R</pub-id>
<pub-id pub-id-type="pmid">31908042</pub-id></mixed-citation></ref><ref id="bph15164-bib-0023"><mixed-citation publication-type="journal" id="bph15164-cit-0024">
<string-name>
<surname>Magalhaes</surname>, <given-names>G. S.</given-names>
</string-name>, <string-name>
<surname>Barroso</surname>, <given-names>L. C.</given-names>
</string-name>, <string-name>
<surname>Reis</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Rodrigues&#x02010;Machado</surname>, <given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Greg&#x000f3;rio</surname>, <given-names>J. F.</given-names>
</string-name>, <string-name>
<surname>Motta&#x02010;Santos</surname>, <given-names>D.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Campagnole&#x02010;Santos</surname>, <given-names>M. J.</given-names>
</string-name> (<year>2018</year>). <article-title>Angiotensin&#x02010;(1&#x02010;7) promotes resolution of eosinophilic inflammation in an experimental model of asthma</article-title>. <source xml:lang="en">Frontiers in Immunology</source>, <volume>9</volume>
<pub-id pub-id-type="doi">10.3389/fimmu.2018.00058</pub-id>
</mixed-citation></ref><ref id="bph15164-bib-0024"><mixed-citation publication-type="journal" id="bph15164-cit-0025">
<string-name>
<surname>Moore</surname>, <given-names>H. B.</given-names>
</string-name>, <string-name>
<surname>Barrett</surname>, <given-names>C. D.</given-names>
</string-name>, <string-name>
<surname>Moore</surname>, <given-names>E. E.</given-names>
</string-name>, <string-name>
<surname>McIntyre</surname>, <given-names>R. C.</given-names>
</string-name>, <string-name>
<surname>Moore</surname>, <given-names>P. K.</given-names>
</string-name>, <string-name>
<surname>Talmor</surname>, <given-names>D. S.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Yaffe</surname>, <given-names>M. B.</given-names>
</string-name> (<year>2020</year>). <article-title>Is there a role for tissue plasminogen activator (tPA) as a novel treatment for refractory COVID&#x02010;19 associated acute respiratory distress syndrome (ARDS)?</article-title>
<source xml:lang="en">The Journal of Trauma and Acute Care Surgery</source>, <volume>88</volume>(<issue>1&#x02013;8</issue>), <fpage>713</fpage>&#x02013;<lpage>714</lpage>. <pub-id pub-id-type="doi">10.1097/TA.0000000000002694</pub-id>
<pub-id pub-id-type="pmid">32281766</pub-id></mixed-citation></ref><ref id="bph15164-bib-0025"><mixed-citation publication-type="journal" id="bph15164-cit-0026">
<string-name>
<surname>Morita</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kuba</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Ichikawa</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Nakayama</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Katahira</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Iwamoto</surname>, <given-names>R.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Imai</surname>, <given-names>Y.</given-names>
</string-name> (<year>2013</year>). <article-title>The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza</article-title>. <source xml:lang="en">Cell</source>, <volume>153</volume>(<issue>1</issue>), <fpage>112</fpage>&#x02013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.02.027</pub-id>
<pub-id pub-id-type="pmid">23477864</pub-id></mixed-citation></ref><ref id="bph15164-bib-0026"><mixed-citation publication-type="journal" id="bph15164-cit-0027">
<string-name>
<surname>Newson</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Motwani</surname>, <given-names>M. P.</given-names>
</string-name>, <string-name>
<surname>Kendall</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Nicolaou</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Muccioli</surname>, <given-names>G. G.</given-names>
</string-name>, <string-name>
<surname>Alhouayek</surname>, <given-names>M.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Gilroy</surname>, <given-names>D. W.</given-names>
</string-name> (<year>2017</year>). <article-title>Inflammatory resolution triggers a prolonged phase of immune suppression through COX&#x02010;1/mPGES&#x02010;1&#x02010;derived prostaglandin E2</article-title>. <source xml:lang="en">Cell Reports</source>, <volume>20</volume>, <fpage>3162</fpage>&#x02013;<lpage>3175</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2017.08.098</pub-id>
<pub-id pub-id-type="pmid">28954232</pub-id></mixed-citation></ref><ref id="bph15164-bib-0027"><mixed-citation publication-type="journal" id="bph15164-cit-0028">
<string-name>
<surname>Norris</surname>, <given-names>P. C.</given-names>
</string-name>, <string-name>
<surname>Libreros</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Chiang</surname>, <given-names>N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Serhan</surname>, <given-names>C. N.</given-names>
</string-name> (<year>2017</year>). <article-title>A cluster of immunoresolvents links coagulation to innate host defense in human blood</article-title>. <source xml:lang="en">Science Signaling</source>, <volume>10</volume>(<issue>490</issue>), <fpage>eaan1471</fpage>
<pub-id pub-id-type="doi">10.1126/scisignal.aan1471</pub-id>
<pub-id pub-id-type="pmid">28765512</pub-id></mixed-citation></ref><ref id="bph15164-bib-0028"><mixed-citation publication-type="journal" id="bph15164-cit-0029">
<string-name>
<surname>Oliveira</surname>, <given-names>L. G.</given-names>
</string-name>, <string-name>
<surname>Souza&#x02010;Testasicca</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>Vago</surname>, <given-names>J. P.</given-names>
</string-name>, <string-name>
<surname>Figueiredo</surname>, <given-names>A. B.</given-names>
</string-name>, <string-name>
<surname>Canavaci</surname>, <given-names>A. M. C.</given-names>
</string-name>, <string-name>
<surname>Perucci</surname>, <given-names>L. O.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Fernandes</surname>, <given-names>A. P.</given-names>
</string-name> (<year>2017</year>). <article-title>Annexin A1 is involved in the resolution of inflammatory responses during Leishmania braziliensis infection</article-title>. <source xml:lang="en">The Journal of Immunology.</source>, <volume>198</volume>, <fpage>3227</fpage>&#x02013;<lpage>3236</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1602028</pub-id>
<pub-id pub-id-type="pmid">28289158</pub-id></mixed-citation></ref><ref id="bph15164-bib-0029"><mixed-citation publication-type="journal" id="bph15164-cit-0030">
<string-name>
<surname>Perretti</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Leroy</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Bland</surname>, <given-names>E. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Montero&#x02010;Melendez</surname>, <given-names>T.</given-names>
</string-name> (<year>2015</year>). <article-title>Resolution pharmacology: Opportunities for therapeutic innovation in inflammation</article-title>. <source xml:lang="en">Trends in Pharmacological Sciences</source>, <volume>36</volume>(<issue>11</issue>), <fpage>737</fpage>&#x02013;<lpage>755</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2015.07.007</pub-id>
<pub-id pub-id-type="pmid">26478210</pub-id></mixed-citation></ref><ref id="bph15164-bib-0030"><mixed-citation publication-type="journal" id="bph15164-cit-0031">
<string-name>
<surname>Rago</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Melo</surname>, <given-names>E. M.</given-names>
</string-name>, <string-name>
<surname>Kraemer</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Galv&#x000e3;o</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Cassali</surname>, <given-names>G. D.</given-names>
</string-name>, <string-name>
<surname>Santos</surname>, <given-names>R. A. S.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Teixeira</surname>, <given-names>M. M.</given-names>
</string-name> (<year>2019</year>). <article-title>Effect of preventive or therapeutic treatment with angiotensin 1&#x02013;7 in a model of bleomycin&#x02010;induced lung fibrosis in mice</article-title>. <source xml:lang="en">Journal of Leukocyte Biology</source>, <volume>106</volume>, <fpage>677</fpage>&#x02013;<lpage>686</lpage>. <pub-id pub-id-type="doi">10.1002/JLB.MA1218-490RR</pub-id>
<pub-id pub-id-type="pmid">31256436</pub-id></mixed-citation></ref><ref id="bph15164-bib-0031"><mixed-citation publication-type="journal" id="bph15164-cit-0032">
<string-name>
<surname>Ramon</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Baker</surname>, <given-names>S. F.</given-names>
</string-name>, <string-name>
<surname>Sahler</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Feldsott</surname>, <given-names>E. A.</given-names>
</string-name>, <string-name>
<surname>Serhan</surname>, <given-names>C. N.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Phipps</surname>, <given-names>R. P.</given-names>
</string-name> (<year>2014</year>). <article-title>The specialized proresolving mediator 17&#x02010;HDHA enhances the antibody&#x02010;mediated immune response against influenza virus: A new class of adjuvant?</article-title>
<source xml:lang="en">The Journal of Immunology.</source>, <volume>193</volume>, <fpage>6031</fpage>&#x02013;<lpage>6040</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1302795</pub-id>
<pub-id pub-id-type="pmid">25392529</pub-id></mixed-citation></ref><ref id="bph15164-bib-0032"><mixed-citation publication-type="journal" id="bph15164-cit-0033">
<string-name>
<surname>Reis</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Alessandri</surname>, <given-names>A. L.</given-names>
</string-name>, <string-name>
<surname>Athayde</surname>, <given-names>R. M.</given-names>
</string-name>, <string-name>
<surname>Perez</surname>, <given-names>D. A.</given-names>
</string-name>, <string-name>
<surname>Vago</surname>, <given-names>J. P.</given-names>
</string-name>, <string-name>
<surname>&#x000c1;vila</surname>, <given-names>T. V.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Pinho</surname>, <given-names>V.</given-names>
</string-name> (<year>2015</year>). <article-title>Induction of eosinophil apoptosis by hydrogen peroxide promotes the resolution of allergic inflammation</article-title>. <source xml:lang="en">Cell Death &#x00026; Disease</source>, <volume>6</volume>(<issue>2</issue>), <elocation-id>e1632</elocation-id>
<pub-id pub-id-type="doi">10.1038/cddis.2014.580</pub-id>
<pub-id pub-id-type="pmid">25675292</pub-id></mixed-citation></ref><ref id="bph15164-bib-0033"><mixed-citation publication-type="journal" id="bph15164-cit-0034">
<string-name>
<surname>Schloer</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>H&#x000fc;bel</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Masemann</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Pajonczyk</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Brunotte</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Ehrhardt</surname>, <given-names>C.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Rescher</surname>, <given-names>U.</given-names>
</string-name> (<year>2019</year>). <article-title>The annexin A1/FPR2 signaling axis expands alveolar macrophages, limits viral replication, and attenuates pathogenesis in the murine influenza A virus infection model</article-title>. <source xml:lang="en">FASEB Journal</source>, <volume>33</volume>(<issue>11</issue>), <fpage>12188</fpage>&#x02013;<lpage>12199</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201901265R</pub-id>
<pub-id pub-id-type="pmid">31398292</pub-id></mixed-citation></ref><ref id="bph15164-bib-0034"><mixed-citation publication-type="journal" id="bph15164-cit-0035">
<string-name>
<surname>Sencio</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Barthelemy</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Tavares</surname>, <given-names>L. P.</given-names>
</string-name>, <string-name>
<surname>Machado</surname>, <given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Soulard</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Cuinat</surname>, <given-names>C.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Trottein</surname>, <given-names>F.</given-names>
</string-name> (<year>2020</year>). <article-title>Gut dysbiosis during influenza contributes to pulmonary pneumococcal superinfection through altered short&#x02010;chain fatty acid production</article-title>. <source xml:lang="en">Cell Reports</source>, <volume>30</volume>(<issue>9</issue>), <fpage>2934</fpage>&#x02013;<lpage>2947.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2020.02.013</pub-id>
<pub-id pub-id-type="pmid">32130898</pub-id></mixed-citation></ref><ref id="bph15164-bib-0035"><mixed-citation publication-type="journal" id="bph15164-cit-0036">
<string-name>
<surname>Shirey</surname>, <given-names>K. A.</given-names>
</string-name>, <string-name>
<surname>Lai</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Pletneva</surname>, <given-names>L. M.</given-names>
</string-name>, <string-name>
<surname>Karp</surname>, <given-names>C. L.</given-names>
</string-name>, <string-name>
<surname>Divanovic</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Blanco</surname>, <given-names>J. C. G.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Vogel</surname>, <given-names>S. N.</given-names>
</string-name> (<year>2014</year>). <article-title>Role of the lipoxygenase pathway in RSV&#x02010;induced alternatively activated macrophages leading to resolution of lung pathology</article-title>. <source xml:lang="en">Mucosal Immunology</source>, <volume>7</volume>(<issue>3</issue>), <fpage>549</fpage>&#x02013;<lpage>557</lpage>. <pub-id pub-id-type="doi">10.1038/mi.2013.71</pub-id>
<pub-id pub-id-type="pmid">24064666</pub-id></mixed-citation></ref><ref id="bph15164-bib-0036"><mixed-citation publication-type="journal" id="bph15164-cit-0037">
<string-name>
<surname>Sim&#x000f5;es E Silva</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Silveira</surname>, <given-names>K. D.</given-names>
</string-name>, <string-name>
<surname>Ferreira</surname>, <given-names>A. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Teixeira</surname>, <given-names>M. M.</given-names>
</string-name> (<year>2013</year>). <article-title>ACE2, angiotensin&#x02010;(1&#x02010;7) and Mas receptor axis in inflammation and fibrosis</article-title>. <source xml:lang="en">British Journal of Pharmacology</source>, <volume>169</volume>, <fpage>477</fpage>&#x02013;<lpage>492</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12159</pub-id>
<pub-id pub-id-type="pmid">23488800</pub-id></mixed-citation></ref><ref id="bph15164-bib-0037"><mixed-citation publication-type="journal" id="bph15164-cit-0038">
<string-name>
<surname>Sugimoto</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Ribeiro</surname>, <given-names>A. L. C.</given-names>
</string-name>, <string-name>
<surname>Costa</surname>, <given-names>B. R. C.</given-names>
</string-name>, <string-name>
<surname>Vago</surname>, <given-names>J. P.</given-names>
</string-name>, <string-name>
<surname>Lima</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Carneiro</surname>, <given-names>F. S.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Sousa</surname>, <given-names>L. P.</given-names>
</string-name> (<year>2017</year>). <article-title>Phagocytes, granulocytes, &#x00026; myelopoiesis: Plasmin &#x00026; plasminogen induce macrophage reprogramming &#x00026; regulate key steps of inflammation resolution via annexin A1</article-title>. <source xml:lang="en">Blood</source>, <volume>129</volume>(<issue>21</issue>), <fpage>2896</fpage>&#x02013;<lpage>2907</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2016-09-742825</pub-id>
<pub-id pub-id-type="pmid">28320709</pub-id></mixed-citation></ref><ref id="bph15164-bib-0038"><mixed-citation publication-type="journal" id="bph15164-cit-0039">
<string-name>
<surname>Sugimoto</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Vago</surname>, <given-names>J. P.</given-names>
</string-name>, <string-name>
<surname>Perretti</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Teixeira</surname>, <given-names>M. M.</given-names>
</string-name> (<year>2019</year>). <article-title>Mediators of the resolution of the inflammatory response</article-title>. <source xml:lang="en">Trends in Immunology</source>, <volume>40</volume>, <fpage>212</fpage>&#x02013;<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2019.01.007</pub-id>
<pub-id pub-id-type="pmid">30772190</pub-id></mixed-citation></ref><ref id="bph15164-bib-0039"><mixed-citation publication-type="journal" id="bph15164-cit-0040">
<string-name>
<surname>Tavares</surname>, <given-names>L. P.</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>, <given-names>C. C.</given-names>
</string-name>, <string-name>
<surname>Vago</surname>, <given-names>J. P.</given-names>
</string-name>, <string-name>
<surname>Queiroz&#x02010;Junior</surname>, <given-names>C. M.</given-names>
</string-name>, <string-name>
<surname>Galv&#x000e3;o</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>David</surname>, <given-names>B. A.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Sousa</surname>, <given-names>L. P.</given-names>
</string-name> (<year>2016</year>). <article-title>Inhibition of phosphodiesterase&#x02010;4 during pneumococcal pneumonia reduces inflammation and lung injury in mice</article-title>. <source xml:lang="en">American Journal of Respiratory Cell and Molecular Biology</source>, <volume>55</volume>(<issue>1</issue>), <fpage>24</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2015-0083OC</pub-id>
<pub-id pub-id-type="pmid">26677751</pub-id></mixed-citation></ref><ref id="bph15164-bib-0040"><mixed-citation publication-type="journal" id="bph15164-cit-0041">
<string-name>
<surname>Tavares</surname>, <given-names>L. P.</given-names>
</string-name>, <string-name>
<surname>Teixeira</surname>, <given-names>M. M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Garcia</surname>, <given-names>C. C.</given-names>
</string-name> (<year>2017</year>). <article-title>The inflammatory response triggered by Influenza virus: A two edged sword</article-title>. <source xml:lang="en">Inflammation Research</source>, <volume>66</volume>, <fpage>283</fpage>&#x02013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1007/s00011-016-0996-0</pub-id>
<pub-id pub-id-type="pmid">27744631</pub-id></mixed-citation></ref><ref id="bph15164-bib-0041"><mixed-citation publication-type="journal" id="bph15164-cit-0042">
<string-name>
<surname>Trentin</surname>, <given-names>P. G.</given-names>
</string-name>, <string-name>
<surname>Ferreira</surname>, <given-names>T. P. T.</given-names>
</string-name>, <string-name>
<surname>Arantes</surname>, <given-names>A. C. S.</given-names>
</string-name>, <string-name>
<surname>Ciambarella</surname>, <given-names>B. T.</given-names>
</string-name>, <string-name>
<surname>Cordeiro</surname>, <given-names>R. S. B.</given-names>
</string-name>, <string-name>
<surname>Flower</surname>, <given-names>R. J.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Silva</surname>, <given-names>P. M. R.</given-names>
</string-name> (<year>2015</year>). <article-title>Annexin A1 mimetic peptide controls the inflammatory and fibrotic effects of silica particles in mice</article-title>. <source xml:lang="en">British Journal of Pharmacology</source>, <volume>172</volume>, <fpage>3058</fpage>&#x02013;<lpage>3071</lpage>. <pub-id pub-id-type="doi">10.1111/bph.13109</pub-id>
<pub-id pub-id-type="pmid">25659822</pub-id></mixed-citation></ref><ref id="bph15164-bib-0042"><mixed-citation publication-type="journal" id="bph15164-cit-0043">
<string-name>
<surname>Vago</surname>, <given-names>J. P.</given-names>
</string-name>, <string-name>
<surname>Sugimoto</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Lima</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Negreiros&#x02010;Lima</surname>, <given-names>G. L.</given-names>
</string-name>, <string-name>
<surname>Baik</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Teixeira</surname>, <given-names>M. M.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Sousa</surname>, <given-names>L. P.</given-names>
</string-name> (<year>2019</year>). <article-title>Plasminogen and the plasminogen receptor, PLG&#x02010;RKT, regulate macrophage phenotypic, and functional changes</article-title>. <source xml:lang="en">Frontiers in Immunology</source>, <volume>10</volume>
<pub-id pub-id-type="doi">10.3389/fimmu.2019.01458</pub-id>
</mixed-citation></ref><ref id="bph15164-bib-0043"><mixed-citation publication-type="journal" id="bph15164-cit-0044">
<string-name>
<surname>Wang</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Anthony</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Yatmaz</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Wijburg</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Satzke</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Levy</surname>, <given-names>B.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Bozinovski</surname>, <given-names>S.</given-names>
</string-name> (<year>2017</year>). <article-title>Aspirin&#x02010;triggered resolvin D1 reduces pneumococcal lung infection and inflammation in a viral and bacterial coinfection pneumonia model</article-title>. <source xml:lang="en">Clinical Science</source>, <volume>131</volume>(<issue>18</issue>), <fpage>2347</fpage>&#x02013;<lpage>2362</lpage>. <pub-id pub-id-type="doi">10.1042/CS20171006</pub-id>
<pub-id pub-id-type="pmid">28779028</pub-id></mixed-citation></ref><ref id="bph15164-bib-0044"><mixed-citation publication-type="journal" id="bph15164-cit-0045">
<string-name>
<surname>Wen</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Su</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Tang</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Le</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>, <given-names>Y.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Wang</surname>, <given-names>H.</given-names>
</string-name> (<year>2020</year>). <article-title>Immune cell profiling of COVID&#x02010;19 patients in the recovery stage by single&#x02010;cell sequencing</article-title>. <source xml:lang="en">Cell Discovery</source>, <volume>6</volume>, <fpage>31</fpage>
<pub-id pub-id-type="doi">10.1038/s41421-020-0168-9</pub-id>
<pub-id pub-id-type="pmid">32377375</pub-id></mixed-citation></ref><ref id="bph15164-bib-0045"><mixed-citation publication-type="journal" id="bph15164-cit-0046">
<string-name>
<surname>Wu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Guo</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Ge</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Huang</surname>, <given-names>Z.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Li</surname>, <given-names>J.</given-names>
</string-name> (<year>2020</year>). <article-title>Plasminogen improves lung lesions and hypoxemia in patients with COVID&#x02010;19</article-title>. <source xml:lang="en">SSRN Electronic Journal</source>, <volume>2</volume>
<pub-id pub-id-type="doi">10.2139/ssrn.3552628</pub-id>
</mixed-citation></ref></ref-list></back></article>